Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Published on Feb 1, 2019in Genetics in Medicine8.822
· DOI :10.1038/S41436-018-0125-2
Hiroki Maruyama26
Estimated H-index: 26
(Niigata University),
Kaori Miyata3
Estimated H-index: 3
+ 28 AuthorsSatoshi Ishii38
Estimated H-index: 38
Source
Abstract
Figures & Tables
Download
References0
Newest
Cited By1
Newest
#1Stefan Vordenbäumen (HHU: University of Düsseldorf)H-Index: 14
#2Ralph Brinks (HHU: University of Düsseldorf)H-Index: 20
Last. Matthias Schneider (HHU: University of Düsseldorf)H-Index: 71
view all 5 authors...
Fabry disease (FD) is a rare lysosomal storage disorder caused by mutations of the alpha-galactosidase A gene ( GLA ) which causes premature morbidity due to organ dysfunction following deposition of globotriaosylceramide (Gb3).1 Presenting symptoms include musculoskeletal pain such as acroparesthesias2 which often result in rheumatological consultations.3 Concerns have been raised that patients with FD are often falsely attributed with classical rheumatological diagnoses, precluding early effec...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.